Population
Patients with chronic heart failure and pulmonary hypertension
Design
Review
Authors
Loading...
Reinforces discouragement of off-label pulmonary vasoactive drugs in CHF-PH; leaves open long-term benefit pending dedicated RCTs.
Highlights the lack of evidence for pulmonary vasodilators in CHF-associated PH and discourages their off-label use while calling for dedicated trials.
Bonderman et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: